{
  "bio": [
    "In 2005, Thomas Struengmann and twin Andreas sold their generic drug firm Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion.",
    "They cofounded Hexal in 1986. The company launched highly successful versions of the cholesterol-lowering drug simvastatin.",
    "The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.",
    "Their venture portfolio includes Germany's BioNTech and Uruguay's Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.",
    "In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann."
  ],
  "about": [
    "After obtaining a business degree from the University of Augsburg, Thomas worked as a marketing manager for Schering-Plough.",
    "Like his twin brother, he is said to be an accomplished golfer and likes to ski. He reportedly collects modern art and Swiss watches."
  ]
}